These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 12227166)

  • 21. The dendritic cell: the immune system's adjuvant--a strategy to develop a HCV vaccine?
    Larsson M
    Gastroenterology; 2006 Feb; 130(2):603-6. PubMed ID: 16472613
    [No Abstract]   [Full Text] [Related]  

  • 22. Frequencies of HCV-specific effector CD4+ T cells by flow cytometry: correlation with clinical disease stages.
    Rosen HR; Miner C; Sasaki AW; Lewinsohn DM; Conrad AJ; Bakke A; Bouwer HG; Hinrichs DJ
    Hepatology; 2002 Jan; 35(1):190-8. PubMed ID: 11786976
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD4+ immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus.
    Puig M; Mihalik K; Tilton JC; Williams O; Merchlinsky M; Connors M; Feinstone SM; Major ME
    Hepatology; 2006 Sep; 44(3):736-45. PubMed ID: 16941702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins.
    Haller AA; Lauer GM; King TH; Kemmler C; Fiolkoski V; Lu Y; Bellgrau D; Rodell TC; Apelian D; Franzusoff A; Duke RC
    Vaccine; 2007 Feb; 25(8):1452-63. PubMed ID: 17098335
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD30 antigen and multiple sclerosis: CD30, an important costimulatory molecule and marker of a regulatory subpopulation of dendritic cells, is involved in the maintenance of the physiological balance between TH1/TH2 immune responses and tolerance. The role of IFNbeta-1a in the treatment of multiple sclerosis.
    Pellegrini P; Totaro R; Contasta I; Berghella AM; Carolei A; Adorno D
    Neuroimmunomodulation; 2005; 12(4):220-34. PubMed ID: 15990453
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Hepatitis C immunology].
    Alvarado Esquivel C; Leroux-Roels G
    Rev Invest Clin; 1999; 51(5):315-22. PubMed ID: 10614142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Involvement of dendritic cell dysfunction in the persistence of hepatitis C virus infection].
    Kanto T; Hayashi N
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):170-4. PubMed ID: 15359787
    [No Abstract]   [Full Text] [Related]  

  • 28. Cytokine mRNA expression in hepatitis C virus infection: TH1 predominance in patients with chronic hepatitis C and TH1-TH2 cytokine profile in subjects with self-limited disease.
    Gigi E; Raptopoulou-Gigi M; Kalogeridis A; Masiou S; Orphanou E; Vrettou E; Lalla TH; Sinakos E; Tsapas V
    J Viral Hepat; 2008 Feb; 15(2):145-54. PubMed ID: 18184198
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Murine dendritic cells pulsed with an anti-idiotype antibody induce antigen-specific protective antitumor immunity.
    Saha A; Chatterjee SK; Foon KA; Primus FJ; Bhattacharya-Chatterjee M
    Cancer Res; 2003 Jun; 63(11):2844-54. PubMed ID: 12782590
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids.
    Geissler M; Gesien A; Tokushige K; Wands JR
    J Immunol; 1997 Feb; 158(3):1231-7. PubMed ID: 9013964
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peripheral-blood mononuclear cell responses to recombinant hepatitis C virus antigens in patients with chronic hepatitis C.
    Schupper H; Hayashi P; Scheffel J; Aceituno S; Paglieroni T; Holland PV; Zeldis JB
    Hepatology; 1993 Nov; 18(5):1055-60. PubMed ID: 7693570
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Chronic hepatitis C: virologic and immunologic aspects].
    Moriya K; Koike K
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):405-7. PubMed ID: 15359831
    [No Abstract]   [Full Text] [Related]  

  • 33. Neutralising antibody, CTL and dendritic cell responses to hepatitis C virus: a preventative vaccine strategy.
    Torresi J; Bharadwaj M; Jackson DC; Gowans EJ
    Curr Drug Targets; 2004 Jan; 5(1):41-56. PubMed ID: 14738217
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Immune response in the pathogenesis of hepatitis C virus infection].
    Chalupa P; Holub M; Davidová A; Arientová S; Beran O
    Epidemiol Mikrobiol Imunol; 2015 Oct; 64(4):198-203. PubMed ID: 26795223
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunopathogenesis of hepatitis C viral infection: Th1/Th2 responses and the role of cytokines.
    Jacobson Brown PM; Neuman MG
    Clin Biochem; 2001 May; 34(3):167-71. PubMed ID: 11408013
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cellular immunity and humoral immunity in non-A, non-B hepatitis].
    Yoshizawa K; Kiyosawa K; Furuta S
    Nihon Rinsho; 1988 Dec; 46(12):2624-8. PubMed ID: 3149333
    [No Abstract]   [Full Text] [Related]  

  • 37. Immune responses in hepatitis C virus infection: the role of dendritic cells.
    Fowler NL; Torresi J; Jackson DC; Brown LE; Gowans EJ
    Immunol Cell Biol; 2003 Feb; 81(1):63-6. PubMed ID: 12534948
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Etiological mechanism of hepatitis C].
    Hayashi N; Hiramatsu N; Fusamoto H; kamata T
    Nihon Naika Gakkai Zasshi; 1994 Feb; 83(2):203-8. PubMed ID: 7963940
    [No Abstract]   [Full Text] [Related]  

  • 39. Maturation of dendritic cells with lipopeptides that represent vaccine candidates for hepatitis C virus.
    Chua BY; Healy A; Cameron PU; Stock O; Rizkalla M; Zeng W; Torresi J; Brown LE; Fowler NL; Gowans EJ; Jackson DC
    Immunol Cell Biol; 2003 Feb; 81(1):67-72. PubMed ID: 12534949
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neonatal adaptive immunity comes of age.
    Adkins B; Leclerc C; Marshall-Clarke S
    Nat Rev Immunol; 2004 Jul; 4(7):553-64. PubMed ID: 15229474
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.